同种异体干细胞联合治疗促进心脏再生的猪模型研究
该研究在实验性缺血性心肌病的Göttingen猪模型中,随机分组接受经心内膜注射同种异体间充质干细胞(MSCs)联合同种异体心脏干细胞(CSCs)、单用MSCs、单用CSCs或安慰剂。结果显示,联合治疗协同减少瘢痕、阻止不良重构并改善收缩功能,且未引发不良免疫反应。
要点
- 同种异体MSCs联合CSCs可协同减少瘢痕并改善收缩功能。
- 联合治疗组未出现不良免疫反应,炎症部位可见免疫耐受性调节性T细胞。
- 该联合策略在猪缺血性心肌病模型中安全有效,值得临床转化。
核心结论
- 同种异体MSCs联合CSCs在猪慢性缺血性心肌病模型中协同促进心脏再生和左室功能恢复,且无不良免疫反应。
- 临床转化至人类是合理的。
研究设计与样本
- 通过心脏磁共振成像和压力容积导管评估,并通过组织学分析检测免疫反应。
主要发现
- 联合治疗组和单用MSCs组瘢痕面积分别减少-11.1 ± 4.8%(p = 0.012)和-9.5 ± 4.8%(p = 0.047)。
- 仅联合治疗组通过抵消 chamber volumes 的增加来阻止持续的不良重构。
- 联合治疗组对收缩功能影响最大,改善收缩末期压力-容积关系(+0.98 ± 0.41 mm Hg/ml;p = 0.016)。
- 联合治疗组心脏某些区域磷酸化组蛋白H3+心肌细胞(p = 0.04)和非心肌细胞(p = 0.0002)多于安慰剂组。
- 联合治疗组和MSC组炎症部位含有免疫耐受性CD3+/CD25+/FoxP3+调节性T细胞(p < 0.0001),组织学显示无至低度炎症浸润,无心肌细胞坏死。
临床怎么用
- 同种异体MSCs联合CSCs可能作为缺血性心肌病再生治疗的一种策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of autologous mesenchymal stem cells (MSCs) and cardiac stem cells (CSCs) synergistically reduces scar size and improves cardiac function in ischemic cardiomyopathy. Whereas allogeneic (allo-)MSCs are immunoevasive, the capacity of CSCs to similarly elude the immune system remains controversial, potentially limiting the success of allogeneic cell combination therapy (ACCT). OBJECTIVES: This study sought to test the hypothesis that ACCT synergistically promotes cardiac regeneration without provoking immunologic reactions. METHODS: Göttingen swine with experimental ischemic cardiomyopathy were randomized to receive transendocardial injections of allo-MSCs + allo-CSCs (ACCT: 200 million MSCs/1 million CSCs, n = 7), 200 million allo-MSCs (n = 8), 1 million allo-CSCs (n = 4), or placebo (Plasma-Lyte A, n = 6). Swine were assessed by cardiac magnetic resonance imaging and pressure volume catheterization. Immune response was tested by histologic analyses. RESULTS: Both ACCT and allo-MSCs reduced scar size by -11.1 ± 4.8% (p = 0.012) and -9.5 ± 4.8% (p = 0.047), respectively. Only ACCT, but not MSCs or CSCs, prevented ongoing negative remodeling by offsetting increases in chamber volumes. Importantly, ACCT exerted the greatest effect on systolic function, improving the end-systolic pressure-volume relation (+0.98 ± 0.41 mm Hg/ml; p = 0.016). The ACCT group had more phospho-histone H3+ (a marker of mitosis) cardiomyocytes (p = 0.04), and noncardiomyocytes (p = 0.0002) than did the placebo group in some regions of the heart. Inflammatory sites in ACCT and MSC-treated swine contained immunotolerant CD3+/CD25+/FoxP3+ regulatory T cells (p < 0.0001). Histologic analysis showed absent to low-grade inflammatory infiltrates without cardiomyocyte necrosis. CONCLUSIONS: ACCT demonstrates synergistic effects to enhance cardiac regeneration and left ventricular functional recovery in a swine model of chronic ischemic cardiomyopathy without adverse immunologic reaction. Clinical translation to humans is warranted.
引用
- Natsumeda M, Florea V, Rieger AC, et al. A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration. J Am Coll Cardiol. 2017. PMID: 29145950. doi:10.1016/j.jacc.2017.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。